Cannabidiol (Epidiolex)

Abstract

CADTH recommends that Epidiolex be reimbursed by public drug plans as adjunctive therapy for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged 2 years and older, if certain conditions are met. Epidiolex should only be covered to treat patients aged 2 years or older who have a clinical diagnosis of seizures associated with LGS and experience at least 2 drop seizures per week over the course of 28 days, and whose seizures are not adequately controlled with 2 or more other antiseizure medications. Epidiolex should be reimbursed if prescribed by a physician with expertise in the diagnosis and management of patients with LGS and if the price of Epidiolex is reduced.